Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.23.5 (cathepsin D)
 4,130 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fibroblast growth from diabetics with poor metabolic control is increased in vitro by 15-92% as compared to healthy age matched controls. In contrast, fibroblast growth from patients with different types of familial hyperlipoproteinemia is decreased by 9-83%. In these fibroblasts the activity of lysosomal cathepsin D, the key enzyme for LDL-apo B degradation, was decreased by 12-31% too. These cell associated alterations could be related to different stages of premature aging. Serum from type II diabetics with poor metabolic control (DS) and from hypercholesterolemics (HS) stimulated growth of human arterial smooth muscle cells and fibroblasts in vitro by 6-64% as compared to serum from healthy controls or to serum from diabetics with good metabolic control. DS increased in these vascular cells LDL- and HDL-binding up to 260%, but decreased LDL-apo B degradation by cathepsin D by 16-39% similar to HS that decreased it by 29-42%. These serum effects depend on the metabolic control and could stimulate the cell turnover. This growth effect of DS is mainly related to at least two new peptides of very low molecular weight (less than 2000 daltons), which might easily penetrate the arterial wall and could contribute to the increased angiopathic risk in diabetes.
 ...
PMID:[Inborn and acquired metabolic disorders in human vascular cells in diabetes mellitus and hyperlipoproteinemia]. 669 64